Expert's Opinion
-
Drug Discovery
The Renaissance of Small Molecule Drug Discovery
In 2021, 62% of new drug approvals were for small molecules, including new treatments for HIV, cancer, infections, heart and kidney disease, and more.Haydn Boehm, Dotmatics 08.03.22
-
QA/QC | Regulatory Affairs
Automation Is Key to Meeting Demands in Pharmacovigilance
To handle the spike in safety reports and improve general efficiencies with adverse event reporting, the industry is turning to newer technologies.Bruce Palsulich, Vice President of Product Strategy, Oracle Health Sciences 08.01.22
-
The Cost-of-Living Crisis and Its Impact on Hiring and Recruitment
In the current economic climate, businesses are having a hard time finding qualified employees they can afford.Neil Kelly, Managing Partner, Vector Partners 07.28.22
-
Drug Development | Drug Discovery | Information Technology
How Polluted Data Lakes Threaten AI in Life Sciences
The problem of reproducibility, potential data problems for AI, and simple starting points for data observability.David Hirko, Founder and principal of Zectonal 07.01.22
-
Why Pride Month Matters to Science
And how you can ensure inclusivity for all.Neil Kelly, Managing Partner, Vector Partners 06.16.22
-
QA/QC | Regulatory Affairs
QSR – ISO Harmonization
All things being equal, they are not—a deeper dive.Ricki Chase, Vice President, Lachman Consultants 06.03.22
-
APIs | cGMP Manufacture | Excipients
Continuous Manufacturing: Building an Evidence Base for Change
CM has the potential to drive productivity and improve safety and product quality but the shift from batch processes requires a robust foundation of knowledge.Mara van Haandel, Innovation Program Director, DFE Pharma, Gericke Bernhard Meir, Head of Continuous Manufacturing (OSD), Gericke AG 05.27.22
-
How to Protect Your Teams from Burnout
From increased workloads to lower engagement levels, burnout has multiple sources and may appear in different guises.Neil Kelly, Managing Partner, Vector Partners 05.19.22
-
Analytical Services | Laboratory Testing
Regulatory Report: Analytical Procedure Development
ICH Q14: Analytical Procedure Development and Revision of Q2(R2) Analytical Validation.Paul Mason, PhD, Senior Director, Lachman Consultants 05.05.22
-
Virtual Interviewing is Here to Stay
While the world is returning to the office, many businesses have made the decision to continue with virtual interviews as a part of their hiring process.Neil Kelly, Managing Partner, Vector Partners 04.28.22
-
Clinical Trials | QA/QC | Regulatory Affairs
Conducting Clinical Trials During the Pandemic: What Did We Learn?
Key takeaways from MHRA's Good Clinical Practice Symposium.David S. O’Connor, Senior Director, Lachman Consultants 04.08.22
-
Clinical Trials | Information Technology
Demystifying Decentralized Clinical Trials
Understanding the advantages and disadvantages, meeting the challenges and creating opportunities.Claudia Berrón, Senior VP, Clinical Services, Avantor 04.05.22
-
A Different Perspective on Recruitment Negotiations
In today’s competitive talent market, the preparation and execution of thoughtful negotiation tactics is even more important than ever before.Neil Kelly, Managing Partner, Vector Partners 03.31.22
-
Information Technology | QA/QC
Achieving Quality Maturity: 5 Key Characteristics of a Next Generation QMS Solution
Pharmaceutical companies must modernize their QMS to provide equal or greater value in today’s world of digital tools and information.Kari Miller, QMS Regulatory and Product Management Leader, Global Tech Solutions, IQVIA 03.28.22
-
Clinical Trials | Drug Development | Information Technology
Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
AI & NLP Technology are critical to overcoming current adverse event processing challenges.Updesh Dosanjh, Practice Leader, Pharmacovigilance Technology Solutions, IQVIA 03.22.22
-
Clinical Trials | GMPs/GCPs | Information Technology
Why Decentralized Clinical Trials Remain a Black Box to Most Research Sites
Overcoming complexity, data, and compliance challenges and how sponsors can help sites become comfortable with DCTs.Catherine Gregor, Chief Clinical Trial Officer at Florence Healthcare 03.18.22
-
Clinical Trials | Information Technology
Is the End of SDTM in Sight?
Evolution is vital in the years ahead if the pharmaceutical industry is going to keep up with new types and dimensions of data.Derk Arts, CEO & Founder, Castor 03.11.22
-
Launching in a Storm: A Year in Recruitment
This is the first in a series of articles to be published monthly on the topic of recruitment and talent acquisition in the pharma industry.Neil Kelly, Managing Partner, Vector Partners 02.24.22
-
cGMP Manufacture | Clinical Trials | Drug Development | Drug Discovery | Information Technology
How Artificial Intelligence and Machine Learning are Transforming the Life Sciences
AI and ML are set to have a measurable impact on drug development, clinical trials, supply chain, and commercial and regulatory processes.Arda Ural, Ernst & Young LLP 01.25.22
-
Clinical Trials | Information Technology
Navigating the Gray Areas: CROs as Consultative Partners
From trial planning, design, operational execution, and ongoing strategic guidance, how sponsors and CROs work hand-in-hand to keep trials moving.Eran Gordon, Senior Vice President, Business Operations, Research & Development Solutions, IQVIA 01.20.22
